How Online GLP-1 Prescriptions Work: what actually happens

GLP-1 medications like semaglutide and tirzepatide have collapsed the distance between "I want help with my weight" and "I have a real pharmacologic tool." But the internet has also collapsed the distance in a less flattering way: fill out a form, get a prescription, no clinical thought in between. A responsible telehealth workflow sits somewhere in the middle — fast, but not thoughtless.

Here is what actually happens on a well-run online GLP-1 program, from the intake form to the monthly refill visit.

Step 1: Eligibility — does this drug even fit you?

The FDA-approved indications for GLP-1s in weight management are specific. For semaglutide (Wegovy) and tirzepatide (Zepbound), eligibility is a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity — hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Equally important is the list of things that make a GLP-1 a bad idea:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Prior severe hypersensitivity to the drug class
• Active pregnancy or plans to become pregnant in the near term
• History of pancreatitis (relative contraindication — requires judgment)
• Severe gastroparesis or active gallbladder disease (also judgment calls)

The intake form should be doing real work here. If it doesn't ask about family thyroid cancer history, that is a red flag about the platform, not a convenience.

Step 2: The labs worth having on file — before you titrate anything

The FDA labeling for both semaglutide and tirzepatide does not mandate specific pre-prescription labs. But the clinical guidelines from AACE and standard obesity medicine practice point to a workup that gives the clinician a real baseline — and catches issues that would change the plan.

If you choose to run bloodwork through us, the panel worth having before starting a GLP-1 typically includes:

• CMP (comprehensive metabolic panel) — kidney and liver function, electrolytes
• HbA1c and fasting glucose — is there undiagnosed diabetes or prediabetes?
• Lipid panel — baseline for cardiovascular risk
• TSH — thyroid function, since weight and thyroid are entangled
• Lipase — a baseline in case of any later abdominal pain workup
• CBC — general health screen
• Vitamin D, B12, ferritin — often low in patients with obesity, and worth tracking if intake drops

None of these are gates. They are context. A patient with an eGFR of 35 gets a different conversation than a patient with an eGFR of 95. A patient with an A1c of 6.8% is being treated for two conditions at once, not one.

The point of baseline labs is not to earn a prescription. It is to make the prescription smarter and the follow-up more meaningful.

Step 3: What the clinician actually checks — beyond the checkbox

A good asynchronous or video visit is not just a form review. The clinician is looking at:

Medication interactions. GLP-1s slow gastric emptying, which can affect absorption of oral medications. Oral contraceptives, thyroid replacement, and certain antibiotics deserve a second look. Insulin and sulfonylureas often need dose reductions to avoid hypoglycemia.

Mental health history. History of eating disorders — particularly restrictive patterns — changes the risk-benefit calculation. Active severe depression with poor appetite is not the same clinical picture as metabolic obesity.

Realistic expectations. The STEP 1 trial of semaglutide 2.4 mg showed a mean weight reduction of about 14.9% at 68 weeks versus 2.4% with placebo. The SURMOUNT-1 trial of tirzepatide 15 mg showed about 20.9% at 72 weeks. Those are averages from tightly-run trials with lifestyle support. Real-world results vary, and "my friend lost 60 pounds" is not a treatment plan.

Titration plan. Both drugs have published escalation schedules — semaglutide starts at 0.25 mg weekly and steps up roughly every four weeks; tirzepatide starts at 2.5 mg weekly with a similar cadence. Titration is not aggressive by design. Going faster to chase results is how people end up with intractable nausea and quit the drug entirely.

The most important takeawayA good online GLP-1 program is defined less by how fast it can send a prescription and more by how carefully it screens, titrates, and follows up.

Step 4: The monthly visit — what it should actually cover

The monthly check-in is where telehealth either earns its keep or exposes itself as a vending machine. A real monthly GLP-1 visit covers:

1. Weight trend — not just this month's number, but the trajectory. A plateau at month 4 is expected. A plateau at month 2 with poor tolerability means we titrate differently. 2. Side effect check — nausea, vomiting, constipation, reflux, injection site reactions, any abdominal pain (especially anything that could suggest pancreatitis or gallbladder disease). 3. Muscle mass and protein intake — GLP-1 weight loss is not selective. Without adequate protein (roughly 1.2–1.6 g/kg of goal body weight for most adults) and resistance training, a meaningful fraction of loss is lean mass. This is a conversation, every visit. 4. Hydration and micronutrients — appetite suppression is the mechanism, and it applies to water and vitamins too. 5. Dose decision — hold, escalate, or de-escalate. There is no rule that says everyone must reach the maximum dose. The right dose is the lowest one that delivers steady progress with tolerable side effects. 6. Labs, when indicated — repeat A1c and lipids at 3–6 months is reasonable. Repeat CMP earlier if there is any concern about hydration or kidney function.

Step 5: When the answer is not yet or not this

The most useful thing an online clinician can do is sometimes decline. Reasons to pause or redirect:

• Symptoms suggesting an untreated eating disorder
• Pregnancy planning within the next 2–3 months (drug should be stopped ~2 months before conception per labeling)
• Uncontrolled gastroparesis symptoms
• New unexplained abdominal pain — that gets worked up, not medicated over
• BMI below the indicated threshold with no qualifying comorbidity

Declining is not gatekeeping. It is the clinical judgment you are paying for.

What to look for in a telehealth GLP-1 program

A short checklist you can use to evaluate any platform, ours included:

• Does the intake ask about thyroid cancer, MEN 2, pancreatitis, and eating disorder history?
• Is there a named clinician, and can you message them between visits?
• Does the program discuss protein intake and resistance training, or only the drug?
• Is titration conservative and individualized, or a fixed monthly escalator?
• Is there a clear plan for what happens if side effects become a problem?
• Are compounded versus FDA-approved options explained honestly, including that compounded medications are not FDA-approved as finished products?

GLP-1s are a genuinely powerful tool for weight and metabolic health. The delivery model — online, monthly, message-based — is not the problem. The absence of clinical thought inside that model is. A good program brings the thought with it.

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. Source
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. Source
3. Garvey WT, Mechanick JI, Brett EM, et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22 Suppl 3:1-203. Source
4. U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. Source
5. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. Source

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.